Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
Psychedelics
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
MindMed announces positive safety and tolerability results from its Phase 1 clinical trial of MM-110 (18-MC) as a treatment for opioid withdrawal.
Albert Labs Granted Health Canada Licence
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
Cybin Inc announces that it will take part in the NYSE's "morning bell" ceremony for the May 18th trading session.
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.
MindMed Announces At-The-Market Offering
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
Major Step Forward For PTSD Treatment And The Psychedelics Industry
A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
DELIC HOLDINGS CORP PROVIDES DEFAULT STATUS UPDATE
Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.